Global Cell Expansion Market, Forecast to 2025 – Increasing Incidence of Chronic Diseases and Government Investments for Cell-based Research – Yahoo…

DUBLIN, July 30, 2020 /PRNewswire/ -- The "Cell Expansion Market by Product (Reagent, Media, Flow Cytometer, Centrifuge, Bioreactor), Cell Type (Human, Animal), Application (Regenerative Medicine & Stem Cell Research, Cancer & Cell-based Research), End-User, and Region - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global cell expansion market is projected to reach USD 30.06 billion by 2025 from an estimated USD 14.91 billion in 2020, at a CAGR of 15.1%.

The report segments the cell expansion market based on region (Asia Pacific, Europe, North America, and RoW), product (consumables and instruments), cell type (human cells and animal cells), application (regenerative medicine and stem cell research, cancer and cell-based research and other applications), and end user (research institutes, biotechnology and biopharmaceutical companies, cell banks, and other end users). The report also provides a comprehensive review of market drivers, restraints, and opportunities in the cell expansion market.

Increasing incidence of chronic diseases and government investments for cell-based research are set to drive the cell expansion market

Growth in this market is largely driven by the increasing incidence of chronic diseases, government investments for cell-based research, growing focus on personalized medicine, increasing focus on R&D for cell-based therapies, and increasing GMP certifications for cell therapy production facilities. On the other hand, ethical concerns regarding research in cell biology are expected to limit market growth to a certain extent in the coming years.

By instruments type, the cell expansion supporting equipment accounted for the fasted growing product segment of the cell expansion market

The instruments segment includes cell expansion supporting equipment, bioreactors, and automated cell expansion systems. The cell expansion supporting equipment market includes flow cytometers, cell counters and hemocytometers, centrifuges, and other supporting equipment. They are used in cell culture processes for isolating, culturing, scaling-up, and extracting biological products. These instruments are essential in laboratories and institutes for conducting research and analyzing the cell structure and function for cell therapy research.

By cell type, the human cells segment accounted for the largest share of the cell expansion market

Based on cell type, the cell expansion market is segmented into human cells and animal cells. The human cells segment includes stem cells and differentiated cells. The stem cells segment is further classified into adult stem cells, ESCs, and iPSCs. The human cells segment accounted for the larger share of the cell expansion market majorly due to the increasing investments by public and private organizations for research on human cells, growing application areas of human stem cells, and the growing incidence of diseases such as cancer.

Asia Pacific: The fastest-growing region in the cell expansion market

The Asia Pacific market is projected to grow at the highest CAGR during the forecast period, mainly due to the increasing focus of players on emerging Asian markets, increasing incidence of chronic and infectious diseases, rising geriatric population, and government initiatives for infrastructural improvements of healthcare facilities are driving the growth of the cell expansion market in this region.

North America: the largest share of the cell expansion market

North America accounted for the largest share of the cell expansion market. The large share of this segment can primarily be attributed to the rising incidence of cancer, increasing government funding, rising research activates on stem cell therapies, growing awareness regarding advanced treatment methods, growing geriatric population, and the strong presence of industry players in the region.

Story continues

Read the original:
Global Cell Expansion Market, Forecast to 2025 - Increasing Incidence of Chronic Diseases and Government Investments for Cell-based Research - Yahoo...

UW researchers devise approach to treat rare, incurable form of blindness – University of Wisconsin-Madison

Scientists at the University of WisconsinMadison have published a proof-of-concept method to correct an inherited form of macular degeneration that causes blindness, and that is currently untreatable.

Andrew Hellpap 608-225-5024 ahellpap@uwhealth.org

The researchers were able to correct the disease in stem cells from patients with BEST1 mutations by overwhelming broken copies of the gene with many functional copies of BEST1. This approach worked for most, but not all, of the BEST1 mutations that they tested. As an alternative approach for mutations that did not respond to this gene augmentation method, the team used CRISPR-Cas9 gene editing to target and correct the mutations.

A paper chronicling the research, co-led by David Gamm, MD, PhD, professor of ophthalmology and visual sciences in the School of Medicine and Public Health, was published online July 23 in the American Journal of Human Genetics. The study was also led by Kris Saha, PhD, associate professor of biomedical engineering and Wisconsin Institute for Discovery, and Bikash Pattnaik, PhD, assistant professor of pediatrics.

This BEST1 gene encodes a protein that regulates the movement of chloride across a layer of the retina called the retinal pigment epithelium (RPE). Best disease is dominant, meaning that people who inherit only one faulty copy of the BEST1 gene from either their mother or their father will develop the disorder. Mutations in BEST1 cause the retinal layer to break down, resulting in blurred central vision that progresses to irreversible vision loss.

People with Best disease have a wide range of mutations that can affect different parts of the protein, all of which were thought to require complex, individualized gene therapies to fix them, Gamm said. We found that many of these mutations were actually very sensitive to a broader gene therapy method that is already established for other retinal diseases.

Fixing a dominant genetic disease via gene therapy typically requires precise removal or repair of the nonfunctional gene without causing harm to the functional gene a difficult task that is frequently unsuccessful. In contrast, recessive genetic diseases that arise when a person inherits two nonfunctional genes one from each parent can be corrected by a technique called gene augmentation. This well-established process introduces a functional copy of the gene to fill the void.

To use another analogy, dominant mutations produce workers that actively look to sabotage the efforts of their capable coworkers, whereas recessive mutations produce proteins that never show up for work at all, Gamm said. As it turns out, the latter situation is usually simpler to treat than the former.

A team of researchers at the McPherson Eye Research Institute, which Gamm directs, hypothesized that it may be possible to adequately dilute the influence of the nonfunctional BEST1 protein by counter-balancing it with many functional copies of BEST1 protein through gene augmentation.

In the lab, the approach worked in RPE cells derived from induced pluripotent stem cells of patients with most, but not all, of the BEST1 gene mutations they tested. Where gene augmentation did not succeed, the team was able to correct the dysfunction using CRISPR-Cas9 gene editing.

The research was carried out in large part by Divya Sinha, PhD, an assistant scientist in Gamms lab, Ben Steyer, a former MD-PhD student in Sahas lab, and Pawan Shahi, PhD, postdoctoral research associate in Pattnaiks lab. The research team also included Sushmita Roy, PhD, associate professor of biostatics and medical informatics at the UW School of Medicine and Public Health and Wisconsin Institute for Discovery.

The scientists demonstrated that their two-pronged gene therapy strategy may hold potential to treat all Best disease mutations in a highly effective manner.

We were able to reverse the disease in all the cell lines using one method or the other, Gamm said. We were also able to determine which mutations were likely to respond to the first-line gene augmentation strategy, and which would be better served with the second-line gene editing approach.

An additional benefit came into focus as this research progressed, according to Gamm.

Our findings also could be applicable to some dominant genetic mutations that affect tissues elsewhere in the body, he said. Its very exciting.

Read the original post:
UW researchers devise approach to treat rare, incurable form of blindness - University of Wisconsin-Madison

A Year After Getting Gene Therapy, Boys With Muscular Dystrophy Are Healthier and Stronger – Singularity Hub

Two and a half years ago, a study published in Science Advances detailed how the gene editing tool CRISPR/Cas-9 repaired genetic mutations related to Duchenne Muscular Dystrophy (DMD). The study was a proof of concept, and used induced pluripotent stem cells (iPSCs).

But now a similar treatment has not only been administered to real people, it has worked and made a difference in their quality of life and the progression of their disorder. Nine boys aged 6 to 12 who have been living with DMD since birth received a gene therapy treatment from pharmaceutical giant Pfizer, and a year later, 7 of the boys show significant improvement in muscle strength and function.

Though the treatments positive results are limited to a small group, theyre an important breakthrough for gene therapy, and encouraging not just for muscular dystrophy but for many other genetic diseases that could soon see similar treatments developed.

DMD is a genetic disorder that causes muscles to progressively degenerate and weaken. Its caused by mutations in the gene that makes dystrophin, a protein that serves to rebuild and strengthen muscle fibers in skeletal and cardiac muscles. As the gene is carried on the X chromosome, the disorder primarily affects boys. Many people with DMD end up in wheelchairs, on respirators, or both, and while advances in cardiac and respiratory care have increased life expectancy into the early 30s, theres no cure for the condition.

The gene therapy given to the nine boys by Pfizer was actually developed by a research team at the UNC Chapel Hill School of Medicineand it took over 30 years.

The team was led by Jude Samulski, a longtime gene therapy researcher and professor of pharmacology at UNC. As a grad student in 1984, Samulski was part of the first team to clone an adeno-associated virus, which ended up becoming a leading method of gene delivery and thus crucial to gene therapy.

Adeno-associated viruses (AAVs) are small viruses whose genome is made up of single-stranded DNA. Like other viruses, AAVs can break through cells outer membranesespecially eye and muscle cellsget inside, and infect them (and their human hosts). But AAVs are non-pathogenic, meaning they dont cause disease or harm; the bodies of most people treated with AAVs dont launch an immune response, because their systems detect that the virus is harmless.

Samulskis gene therapy treatment for DMD used an adeno-associated virus to carry a healthy copy of the dystrophin gene; the virus was injected into boys with DMD, broke into their muscle cells, and replaced their non-working gene.

Samulski said of the adeno-associated virus, Its a molecular FedEx truck. It carries a genetic payload and its delivering it to its target. The company Samulski founded sold the DMD treatment to Pfizer in 2016 so as to scale it and make it accessible to more boys suffering from the condition.

A year after receiving the gene therapy, seven of nine boys are showing positive results. As reported by NPR, the first boy to be treated, a nine-year old from Connecticut, saw results that were not only dramatic, but fast. Before treatment he couldnt walk up more than four stairs without needing to stop, but within three weeks of treatment he was able to run up the full flight of stairs. I can run faster. I stand better. And I can walk [] more than two miles and I couldnt do that before, he said.

The muscle cells already lost to DMD wont grow back, but the treatment appears to have restored normal function of the protein that fixes muscle fibers and helps them grow, meaning no further degeneration should take place.

Gene therapy trials are underway for several different genetic diseases, including sickle cell anemia, at least two different forms of inherited blindness, and Alzheimers, among others. Its even been used as part of cancer treatment.

Its only been a year, we dont yet know whether these treatments may have some sort of detrimental effect in the longer term, and the treatment itself can still be improved. But all of that considered, signs point to the DMD treatment being a big win for gene therapy.

Before it can be hailed as a resounding success, though, scientists feel that a more extensive trial of the therapy is needed, and are working to launch such a trial later this year.

Image Credit: pixelRaw from Pixabay

More:
A Year After Getting Gene Therapy, Boys With Muscular Dystrophy Are Healthier and Stronger - Singularity Hub

Global Regenerative Medicine Market 2020| Industry Demand, Share, Global Trend, Industry News, Business Growth, Top Key Players Update, Business…

Global Regenerative Medicine Market industry is anticipated to an extensive growth during the forecast period 2018-2023. Regenerative Medicine Market report provides in detail analysis of market with revenue growth and upcoming trends. report contains the forecasts, market size, share estimates and profiles of the leading industry Players.

Regenerative Medicine Market research report provides derived key statistics, based on the market status of the manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Regenerative Medicine industry. The report is a reliable analysis of current scenario of the market, which covers several market dynamics.

Get a Sample Copy Of The Report At https://www.absolutereports.com/enquiry/request-sample/13100563

The global regenerative medicine market has been estimated to reach USD 4.23 billion in 2023. The market is expected to register a CAGR of 14% during the forecast period 2018 to 2023. North America dominates the market due to the increasing technological advancements.

Increasing adoption of stem cell technology

Increasing adoption of stem cell technology, increasing prevalence of chronic diseases, emerging applications of gene therapy in regenerative medicine are some of the driving factors for Global Regenerative Medicine market. Technological advances in regenerative medicine (stem cell, tissue engineering, and nanotechnology) and high investment & funding to support development of regenerative medicine are also fuelling the market growth.

Regulatory and ethical issues

Regulatory and ethical issues pertaining stem cell, tissues engineering and regenerative medicine are acting as a restraint for Regenerative Medicine market. High cost of treatments and less awareness about the regenerative medicine among people is further restraining the market.

North America to Dominate the Market

The Regenerative Medicine market is segmented by type of treatment and geography. By geography it is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa and South America. North America dominates the Regenerative Medicine market due to the increasing technological advancements and high investment & funding to support development of regenerative medicine. Asia-Pacific is also expected to propel the Regenerative Medicine market owing to factors, such as increasing accessibility to healthcare facilities in the region, and increasing economic growth.

Key Developments in the market

In January, 2018: Medeor Therapeutics Awarded $18.8 Million From the California Institute for Regenerative Medicine In January, 2018: RepliCel Life Sciences Inc. formed a partnership with the private firm, China-based Yofoto Health Industry Co. Ltd for regenerative medicine

Major Key Players: ACELITY, OSIRIS THERAPEUTICS, INC., INTEGRA LIFESCIENCES CORPORATION, ASTRAZENECA, COOK BIOTECH INCORPORATED, ORGANOGENESIS INC. and MERCK & CO., INC. etc.

Major Regions: US, Canada, Rest of North America, China, Japan, India, Rest of Asia-Pacific, Germany, UK, France, Rest of Europe, Brazil, South Africa, Rest of the World,

Inquire Or Share Your Questions If Any Before The Purchasing This Report https://www.absolutereports.com/enquiry/pre-order-enquiry/13100563

Reasons to Purchase this Report:

Major Points Covered in Table of Content of Regenerative Medicine Market forecast 2023

1. Introduction of Regenerative Medicine Market Report

1.1 Study Deliverables

1.2 General Study Assumptions

2. Research Methodology

2.1 Introduction

2.2 Analysis Methodology

2.3 Study Phases

2.4 Econometric Modelling

3. Executive Summary

4. Market Overview and Regenerative Medicine Market Trends

4.1 Introduction

4.2 Market Trends

4.3 Porters Five Force Framework

4.3.1 Bargaining Power of Suppliers

4.3.2 Bargaining Power of Consumers

4.3.3 Threat of New Entrants

4.3.4 Threat of Substitute Products and Services

4.3.5 Competitive Rivalry within the Industry

5. Regenerative Medicine Market Dynamics

5.1 Drivers

5.2 Restraints

5.3 Opportunities

6. Global Regenerative Medicine Market, Segmented by Size

7. Global Regenerative Medicine Market, Segmented by Technology Type

Purchase This Report (Price 4250 USD for single user license) https://www.absolutereports.com/purchase/13100563

8. Global Regenerative Medicine Market, Segmented by Geography

8.1 North America

8.1.1 United States

8.1.2 Canada

8.1.3 Mexico

8.1.4 Others

8.2 South America

8.2.1 Brazil

8.2.2 Argentina

8.2.3 Others

8.3 Asia-Pacific

8.3.1 China

8.3.2 Japan

8.3.3 India

8.3.4 Others

8.4 Europe

8.4.1 United Kingdom

8.4.2 Germany

8.4.3 France

8.4.4 Others

8.5 Africa and Middle East

8.5.1 UAE

8.5.2 South Africa

8.5.3 Saudi Arabia

8.5.4 Others

9. Competitive Landscape

9.1 Introduction

9.2 Market Share Analysis

9.3 Developments of Key Players

10. Key Vendor Analysis (Overview, Products & Services, Strategies)

11. Future Outlook of the Market

12. Disclaimer

And Many More.

For Detail TOC Click Here

About Absolute Reports:

Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.

Contact Info:

Name: Ajay More

Email: [emailprotected]

Organization: Absolute Reports

Phone: +14242530807/+44203239 8187

Our Other report : Glass Paint Market 2020 Report Presents an Overall Analysis, Development Trends, Driving Forces, Opportunities & Future Potential 2024

Dental Glass Market 2020 Report Presents an Overall Analysis, Development Trends, Driving Forces, Opportunities & Future Potential 2024

Machine Glazed Paper Market 2020 Analysis Manufacturing Cost Structure, Industry Chain Structure, Raw Material and Suppliers Opportunities & Future Potential 2024

Metal Primers Market 2020 Overview Industry, Definition, Specifications and Classification and Forecast to 2024

Global Black Chinese Wolfberry Market2020Production, Revenue, Price and Gross Margin Analysis with Forecasts to 2026

Medical Tuning Forks Market Mergers & Acquisitions, Expansion, Concentration Rate Outlook (2020-2024)

Touch Screen Market Outlook 2026: Market Trends, Segmentation, Market Growth and Competitive Landscape

Global Mother Boards Market 2020 Overview, Cost Structure Analysis, Growth Opportunities and Forecast to 2026

Global Cold Form Foil Market 2020 Key Players, Industry Overview, Supply Chain and Analysis to 2026

Global Stainless Steel Pipe Board Market 2020 analysis with Key Players, Applications, Trends and Forecasts by 2025

PV Tabbing Ribbon Market Size 2020 Industry Demand, Share, Trend, Industry News, Growth, Top Key Players, Business Statistics and Forecast to 2026

Read the original here:
Global Regenerative Medicine Market 2020| Industry Demand, Share, Global Trend, Industry News, Business Growth, Top Key Players Update, Business...

Qkine bolsters top team in first phase of scale-up – Business Weekly

Qkine a Cambridge-based specialist developer and manufacturer of proteins for stem cell, organoid and regenerative medicine applications has begun scaling following its recent fundraising round.

It has made key hires with the appointments of Rob Nixon as head of Commercial to its management team and Dr Cassie Doherty, investment director at Parkwalk, to its board.

With years of experience working with fast-growing biotechs and life science reagent suppliers, these appointments will be key to supporting the scale-up of Qkines commercial operations globally and expansion of its product development pipeline.

Nixon will implement the scale-up of the companys commercial strategy globally whilst building and leading Qkines growing commercial team. He has extensive commercial experience in the life science sector, having worked for world-leading global life science reagent companies Merck Millipore and GE Healthcare Life Science, as well as emerging, fast-growing startup Jellagen.

His experience in building and coaching highly successful sales teams, implementing go-to-market strategies and developing global distributor networks across the stem cell, organoid and regenerative medicine markets will accelerate the expansion of Qkines commercial operations across both existing and new markets.

Nixon said: There is a clear need in the stem cell culture and organoid research space for innovation. Customers are looking for expertise to improve growth factor biochemical quality, allowing for more reproducible and scalable manufacture of these core proteins to address the tremendous growth of these areas of research.

Dr Doherty becomes a non-executive director following Q Kines 1.5m series A investment round in June, which was led by Parkwalk. Her background in biochemistry and molecular biology, combined with over 10 years of extensive experience in life science investment, will be key to Qkine moving forwards as will her active style when it comes to supporting portfolio companies; advising on strategy, technical and commercial plans as Qkine continues to scale.

To date, companies Dr Doherty has worked with have cumulatively raised over 50 million in investment and she has been involved in many M & A and licensing deals.

She said: Qkines products fill a market need for high-quality protein reagents and clearly address problems that I have seen in companies working in the regenerative medicine, organoid and stem cell space.

See the article here:
Qkine bolsters top team in first phase of scale-up - Business Weekly

$30+ Billion Cell Expansion Market by Product, Cell Type, Application, End-user and Region – Forecast to 2025 – ResearchAndMarkets.com – Business Wire

DUBLIN--(BUSINESS WIRE)--The "Cell Expansion Market by Product (Reagent, Media, Flow Cytometer, Centrifuge, Bioreactor), Cell Type (Human, Animal), Application (Regenerative Medicine & Stem Cell Research, Cancer & Cell-based Research), End-User, and Region - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The global cell expansion market is projected to reach USD 30.06 billion by 2025 from an estimated USD 14.91 billion in 2020, at a CAGR of 15.1%.

The report segments the cell expansion market based on region (Asia Pacific, Europe, North America, and RoW), product (consumables and instruments), cell type (human cells and animal cells), application (regenerative medicine and stem cell research, cancer and cell-based research and other applications), and end user (research institutes, biotechnology and biopharmaceutical companies, cell banks, and other end users). The report also provides a comprehensive review of market drivers, restraints, and opportunities in the cell expansion market.

Increasing incidence of chronic diseases and government investments for cell-based research are set to drive the cell expansion market

Growth in this market is largely driven by the increasing incidence of chronic diseases, government investments for cell-based research, growing focus on personalized medicine, increasing focus on R&D for cell-based therapies, and increasing GMP certifications for cell therapy production facilities. On the other hand, ethical concerns regarding research in cell biology are expected to limit market growth to a certain extent in the coming years.

By instruments type, the cell expansion supporting equipment accounted for the fasted growing product segment of the cell expansion market

The instruments segment includes cell expansion supporting equipment, bioreactors, and automated cell expansion systems. The cell expansion supporting equipment market includes flow cytometers, cell counters and hemocytometers, centrifuges, and other supporting equipment. They are used in cell culture processes for isolating, culturing, scaling-up, and extracting biological products. These instruments are essential in laboratories and institutes for conducting research and analyzing the cell structure and function for cell therapy research.

By cell type, the human cells segment accounted for the largest share of the cell expansion market

Based on cell type, the cell expansion market is segmented into human cells and animal cells. The human cells segment includes stem cells and differentiated cells. The stem cells segment is further classified into adult stem cells, ESCs, and iPSCs. The human cells segment accounted for the larger share of the cell expansion market majorly due to the increasing investments by public and private organizations for research on human cells, growing application areas of human stem cells, and the growing incidence of diseases such as cancer.

Asia Pacific: The fastest-growing region in the cell expansion market

The Asia Pacific market is projected to grow at the highest CAGR during the forecast period, mainly due to the increasing focus of players on emerging Asian markets, increasing incidence of chronic and infectious diseases, rising geriatric population, and government initiatives for infrastructural improvements of healthcare facilities are driving the growth of the cell expansion market in this region.

North America: the largest share of the cell expansion market

North America accounted for the largest share of the cell expansion market. The large share of this segment can primarily be attributed to the rising incidence of cancer, increasing government funding, rising research activates on stem cell therapies, growing awareness regarding advanced treatment methods, growing geriatric population, and the strong presence of industry players in the region.

Company Profiles

Established Companies

Start-up Companies

For more information about this report visit https://www.researchandmarkets.com/r/y35ufs

More:
$30+ Billion Cell Expansion Market by Product, Cell Type, Application, End-user and Region - Forecast to 2025 - ResearchAndMarkets.com - Business Wire

Waveguide Combiners & Dividers Market 2020 Global Share, Growth, Size, Opportunities, Trends, Regional Overview, Leading Company Analysis, And Key…

QY Research has Published Latest Trending Report on Global Waveguide Combiners & Dividers Market

Los Angeles, United State, The report titledGlobal Waveguide Combiners & Dividers Marketis one of the most comprehensive and important additions to QY Researchs archive of market research studies. It offers detailed research and analysis of key aspects of the global Waveguide Combiners & Dividers market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Waveguide Combiners & Dividers market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Waveguide Combiners & Dividers market is carefully analyzed and researched about by the market analysts.

Request Sample Report and Full Report TOC:https://www.qyresearch.com/sample-form/form/1752465/covid-19-impact-on-waveguide-combiners-amp-dividers-market

The Essential Content Covered in the GlobalWaveguide Combiners & Dividers Market Report:

* Top Key Company Profiles. * Main Business and Rival Information * SWOT Analysis and PESTEL Analysis * Production, Sales, Revenue, Price and Gross Margin * Market Share and Size

Global Waveguide Combiners & Dividers Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during 2020-2026. According to the latest report added to the online repository of QY Research the Waveguide Combiners & Dividers market has witnessed an unprecedented growth till 2020. The extrapolated future growth is expected to continue at higher rates by 2025.

Top Players of Waveguide Combiners & Dividers Market are Studied: Cernex Inc, COM DEV International, L-3 Narda-ATM, MCLI, Microwave Engineering Corporation, Muegge GMBH, SAGE Millimeter, Sylatech Limited, Xian HengDa Microwave, etc.

The report provides a 6-year forecast (2020-2026) assessed based on how the Waveguide Combiners & Dividers market is predicted to grow in major regions likeUSA, Europe, Japan, China, India, Southeast Asia, South America, South Africa, Others.

Segmentation by Type:, 3dB Waveguide Combiner/Divider, 3dB Hybrid Waveguide Combiner/Divider, Variable Power Divider

Segmentation by Application:, Commercial, Military, Space

Reasons to Buy this Report:

Table of Contents

1.1 Research Scope 1.2 Market Segmentation 1.3 Research Objectives 1.4 Research Methodology 1.4.1 Research Process 1.4.2 Data Triangulation 1.4.3 Research Approach 1.4.4 Base Year 1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections 1.5.2 Covid-19 Impact: Commodity Prices Indices 1.5.3 Covid-19 Impact: Global Major Government Policy 1.6 The Covid-19 Impact on Human Embryonic Stem Cells (HESC) Industry 1.7 COVID-19 Impact: Human Embryonic Stem Cells (HESC) Market Trends 2 Global Human Embryonic Stem Cells (HESC) Quarterly Market Size Analysis 2.1 Human Embryonic Stem Cells (HESC) Business Impact Assessment COVID-19 2.1.1 Global Human Embryonic Stem Cells (HESC) Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 2.1.2 Global Human Embryonic Stem Cells (HESC) Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 2.2 Global Human Embryonic Stem Cells (HESC) Quarterly Market Size 2020-2021 2.3 COVID-19-Driven Market Dynamics and Factor Analysis 2.3.1 Drivers 2.3.2 Restraints 2.3.3 Opportunities 2.3.4 Challenges 3 Quarterly Competitive Assessment, 2020 3.1 Global Human Embryonic Stem Cells (HESC) Quarterly Market Size by Manufacturers, 2019 VS 2020 3.2 Global Human Embryonic Stem Cells (HESC) Factory Price by Manufacturers 3.3 Location of Key Manufacturers Human Embryonic Stem Cells (HESC) Manufacturing Factories and Area Served 3.4 Date of Key Manufacturers Enter into Human Embryonic Stem Cells (HESC) Market 3.5 Key Manufacturers Human Embryonic Stem Cells (HESC) Product Offered 3.6 Mergers & Acquisitions, Expansion Plans 4 Impact of Covid-19 on Human Embryonic Stem Cells (HESC) Segments, By Type 4.1 Introduction 1.4.1 Totipotent Stem Cells 1.4.2 Pluripotent Stem Cells 1.4.3 Unipotent Stem Cells 4.2 By Type, Global Human Embryonic Stem Cells (HESC) Market Size, 2019-2021 4.2.1 By Type, Global Human Embryonic Stem Cells (HESC) Market Size by Type, 2020-2021 4.2.2 By Type, Global Human Embryonic Stem Cells (HESC) Price, 2020-2021 5 Impact of Covid-19 on Human Embryonic Stem Cells (HESC) Segments, By Application 5.1 Overview 5.5.1 Research 5.5.2 Clinical Trials 5.5.3 Others 5.2 By Application, Global Human Embryonic Stem Cells (HESC) Market Size, 2019-2021 5.2.1 By Application, Global Human Embryonic Stem Cells (HESC) Market Size by Application, 2019-2021 5.2.2 By Application, Global Human Embryonic Stem Cells (HESC) Price, 2020-2021 6 Geographic Analysis 6.1 Introduction 6.2 North America 6.2.1 Macroeconomic Indicators of US 6.2.2 US 6.2.3 Canada 6.3 Europe 6.3.1 Macroeconomic Indicators of Europe 6.3.2 Germany 6.3.3 France 6.3.4 UK 6.3.5 Italy 6.4 Asia-Pacific 6.4.1 Macroeconomic Indicators of Asia-Pacific 6.4.2 China 6.4.3 Japan 6.4.4 South Korea 6.4.5 India 6.4.6 ASEAN 6.5 Rest of World 6.5.1 Latin America 6.5.2 Middle East and Africa 7 Company Profiles 7.1 ESI BIO 7.1.1 ESI BIO Business Overview 7.1.2 ESI BIO Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 2020 7.1.3 ESI BIO Human Embryonic Stem Cells (HESC) Product Introduction 7.1.4 ESI BIO Response to COVID-19 and Related Developments 7.2 Thermo Fisher 7.2.1 Thermo Fisher Business Overview 7.2.2 Thermo Fisher Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 2020 7.2.3 Thermo Fisher Human Embryonic Stem Cells (HESC) Product Introduction 7.2.4 Thermo Fisher Response to COVID-19 and Related Developments 7.3 BioTime 7.3.1 BioTime Business Overview 7.3.2 BioTime Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 2020 7.3.3 BioTime Human Embryonic Stem Cells (HESC) Product Introduction 7.3.4 BioTime Response to COVID-19 and Related Developments 7.4 MilliporeSigma 7.4.1 MilliporeSigma Business Overview 7.4.2 MilliporeSigma Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 2020 7.4.3 MilliporeSigma Human Embryonic Stem Cells (HESC) Product Introduction 7.4.4 MilliporeSigma Response to COVID-19 and Related Developments 7.5 BD Biosciences 7.5.1 BD Biosciences Business Overview 7.5.2 BD Biosciences Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 2020 7.5.3 BD Biosciences Human Embryonic Stem Cells (HESC) Product Introduction 7.5.4 BD Biosciences Response to COVID-19 and Related Developments 7.6 Astellas Institute of Regenerative Medicine 7.6.1 Astellas Institute of Regenerative Medicine Business Overview 7.6.2 Astellas Institute of Regenerative Medicine Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 2020 7.6.3 Astellas Institute of Regenerative Medicine Human Embryonic Stem Cells (HESC) Product Introduction 7.6.4 Astellas Institute of Regenerative Medicine Response to COVID-19 and Related Developments 7.7 Asterias Biotherapeutics 7.7.1 Asterias Biotherapeutics Business Overview 7.7.2 Asterias Biotherapeutics Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 2020 7.7.3 Asterias Biotherapeutics Human Embryonic Stem Cells (HESC) Product Introduction 7.7.4 Asterias Biotherapeutics Response to COVID-19 and Related Developments 7.8 Cell Cure Neurosciences 7.8.1 Cell Cure Neurosciences Business Overview 7.8.2 Cell Cure Neurosciences Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 2020 7.8.3 Cell Cure Neurosciences Human Embryonic Stem Cells (HESC) Product Introduction 7.8.4 Cell Cure Neurosciences Response to COVID-19 and Related Developments 7.9 PerkinElmer 7.9.1 PerkinElmer Business Overview 7.9.2 PerkinElmer Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 2020 7.9.3 PerkinElmer Human Embryonic Stem Cells (HESC) Product Introduction 7.9.4 PerkinElmer Response to COVID-19 and Related Developments 7.10 Takara Bio 7.10.1 Takara Bio Business Overview 7.10.2 Takara Bio Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 2020 7.10.3 Takara Bio Human Embryonic Stem Cells (HESC) Product Introduction 7.10.4 Takara Bio Response to COVID-19 and Related Developments 7.11 Cellular Dynamics International 7.11.1 Cellular Dynamics International Business Overview 7.11.2 Cellular Dynamics International Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 2020 7.11.3 Cellular Dynamics International Human Embryonic Stem Cells (HESC) Product Introduction 7.11.4 Cellular Dynamics International Response to COVID-19 and Related Developments 7.12 Reliance Life Sciences 7.12.1 Reliance Life Sciences Business Overview 7.12.2 Reliance Life Sciences Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 2020 7.12.3 Reliance Life Sciences Human Embryonic Stem Cells (HESC) Product Introduction 7.12.4 Reliance Life Sciences Response to COVID-19 and Related Developments 7.13 Research & Diagnostics Systems 7.13.1 Research & Diagnostics Systems Business Overview 7.13.2 Research & Diagnostics Systems Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 2020 7.13.3 Research & Diagnostics Systems Human Embryonic Stem Cells (HESC) Product Introduction 7.13.4 Research & Diagnostics Systems Response to COVID-19 and Related Developments 7.14 SABiosciences 7.14.1 SABiosciences Business Overview 7.14.2 SABiosciences Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 2020 7.14.3 SABiosciences Human Embryonic Stem Cells (HESC) Product Introduction 7.14.4 SABiosciences Response to COVID-19 and Related Developments 7.15 STEMCELL Technologies 7.15.1 STEMCELL Technologies Business Overview 7.15.2 STEMCELL Technologies Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 2020 7.15.3 STEMCELL Technologies Human Embryonic Stem Cells (HESC) Product Introduction 7.15.4 STEMCELL Technologies Response to COVID-19 and Related Developments 7.16 Stemina Biomarker Discovery 7.16.1 Stemina Biomarker Discovery Business Overview 7.16.2 Stemina Biomarker Discovery Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 2020 7.16.3 Stemina Biomarker Discovery Human Embryonic Stem Cells (HESC) Product Introduction 7.16.4 Stemina Biomarker Discovery Response to COVID-19 and Related Developments 7.17 Takara Bio 7.17.1 Takara Bio Business Overview 7.17.2 Takara Bio Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 2020 7.17.3 Takara Bio Human Embryonic Stem Cells (HESC) Product Introduction 7.17.4 Takara Bio Response to COVID-19 and Related Developments 7.18 TATAA Biocenter 7.18.1 TATAA Biocenter Business Overview 7.18.2 TATAA Biocenter Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 2020 7.18.3 TATAA Biocenter Human Embryonic Stem Cells (HESC) Product Introduction 7.18.4 TATAA Biocenter Response to COVID-19 and Related Developments 7.19 UK Stem Cell Bank 7.19.1 UK Stem Cell Bank Business Overview 7.19.2 UK Stem Cell Bank Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 2020 7.19.3 UK Stem Cell Bank Human Embryonic Stem Cells (HESC) Product Introduction 7.19.4 UK Stem Cell Bank Response to COVID-19 and Related Developments 7.20 ViaCyte 7.20.1 ViaCyte Business Overview 7.20.2 ViaCyte Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 2020 7.20.3 ViaCyte Human Embryonic Stem Cells (HESC) Product Introduction 7.20.4 ViaCyte Response to COVID-19 and Related Developments 7.21 Vitrolife 7.21.1 Vitrolife Business Overview 7.21.2 Vitrolife Human Embryonic Stem Cells (HESC) Quarterly Production and Revenue, 2020 7.21.3 Vitrolife Human Embryonic Stem Cells (HESC) Product Introduction 7.21.4 Vitrolife Response to COVID-19 and Related Developments 8 Supply Chain and Sales Channels Analysis 8.1 Human Embryonic Stem Cells (HESC) Supply Chain Analysis 8.1.1 Human Embryonic Stem Cells (HESC) Supply Chain Analysis 8.1.2 Covid-19 Impact on Human Embryonic Stem Cells (HESC) Supply Chain 8.2 Distribution Channels Analysis 8.2.1 Human Embryonic Stem Cells (HESC) Distribution Channels 8.2.2 Covid-19 Impact on Human Embryonic Stem Cells (HESC) Distribution Channels 8.2.3 Human Embryonic Stem Cells (HESC) Distributors 8.3 Human Embryonic Stem Cells (HESC) Customers 9 Key Findings 10 Appendix 10.1 About Us 10.2 Disclaimer

About US

QY Research is a leading global market research and consulting company. Established in 2007 in Beijing, China, QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and custom research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services.

Go here to read the rest:
Waveguide Combiners & Dividers Market 2020 Global Share, Growth, Size, Opportunities, Trends, Regional Overview, Leading Company Analysis, And Key...

Centre for Commercialization of Cancer Immunotherapy and Regenerative Medicine and the Ontario Institute for Regenerative Medicine Partner to Boost…

TORONTO & MONTREAL--(BUSINESS WIRE)--Regenerative medicine (RM) has the potential to transform healthcare by developing curative therapies for diseases such as heart failure or vision loss. By repairing damaged tissues and organs, this will not only improve patients lives but create economic impact in a market forecasted to reach $5.6B USD by 2025.

Several Canadian-made cell therapies will take a major step closer to the clinic thanks to a new collaboration between the Ontario Institute for Regenerative Medicine (OIRM) and the Centre for Commercialization of Cancer Immunotherapy and Regenerative Medicine (C3i).

Each organization will leverage their unique resources and expertise to help Canadian research teams overcome common but significant hurdles in the RM translational process, from clinical trials through to therapeutic application.

C3i is a funded Centre of Excellence in Commercialization and Research of the federal governments Networks of Centres of Excellence program. It accelerates the development of cancer immunotherapies and cellular-based therapies by providing one-stop-shop services in the chain of product development through to commercialization, as well as supporting Canadian-based companies working in this space.

OIRM is a comprehensive clinical translation ecosystem in Ontario focused on translating promising RM research from the lab to the clinic. Unfortunately, OIRMs core provincial funding was not renewed, compromising multiple world-class translational research programs at pivotal points in clinical development.

Our partnership with C3i is truly a win-win for both organizations, for RM research in Ontario and Canada, and for the health of Canadians, says Dr. Duncan Stewart, President and Scientific Director, OIRM. With C3is deep commercialization resources and manufacturing expertise, OIRM will be able to shift our translational pipeline into high gear. In turn, OIRM will help C3i achieve lateral growth in the RM field on par with their impact to date in the field of cancer immunotherapy.

The CEO of C3i, Mr. Benoit Deschamps, says: We believe that the C3i-OIRM partnership truly expands the one-stop-shop model in supporting cell and gene therapies for Canadian technologies.

In addition to supporting commercialization and manufacturing activities, OIRM and C3i will launch a joint Industry and Investor Program that will include pitch days technology scouting calls tailored to the interested organization as well as opportunities to work alongside researchers to develop strategic solutions needed to advance technologies through the pipeline.

The C3i-OIRM partnership will be guided via a joint steering committee. The OIRM administrative centre and a satellite office for C3i will share space in Torontos MaRS Discovery District.

As part of its Canadian mandate, C3i is excited to expand the Ontario-Quebec corridor and support innovation, ensuring that Canadian technology in cell and gene therapy space can flourish and remain accessible to Canadians, said Mr. Deschamps.

Read the original post:
Centre for Commercialization of Cancer Immunotherapy and Regenerative Medicine and the Ontario Institute for Regenerative Medicine Partner to Boost...

It’s Time to ‘Be The Match,’ Help Save a Life – SCVNEWS.com

Be the Match: Every three minutes, someone is diagnosed with a life-threatening blood cancer or blood disease, such as leukemia, lymphoma or sickle cell disease, and you might be able to help.

For those thousands, a cure exists, though about 70% of patients dont find it within their own families.

Thats why the College of the Canyons Biology Club is partnering with Be The Match to host a drive-in community registry event, where the community is invited to register to be a potential match for someone in need of a life-saving stem cell transplant through a simple swab test.

The science of stem cells is incredible, and it can actually cure over 70 different life-threatening diseases, said Christine Mantilla, member engagement, enrollment and experience specialist at Be The Match. A small population of stem cells from a donor can regenerate an entire bodys worth of bone marrow.

Biology Club President Brian Estarella-Murphy has been on the registry for two years, eagerly awaiting the day hes a match.

For Estarella-Murphy, its personal, as he has had two close friends with blood disorders and has seen firsthand the struggle of some of these patients.

I interned and shadowed at a hospital and a clinic, he added. Ive seen many patients come in that are on their last chance of life, and Id love to be able to give someone that possibility of living their full life without having to worry.

Being involved with the organization has actually changed his career aspirations, motivating him to go into the research side of medicine.

Im a cellular biology major, and the type of research that they do on these swab tests are exactly what I want to do in the future, he added. I want to pick apart these cells to see how I can help advance medicine (to create) life-saving treatment.

So upon taking up presidency of the club, Estarella-Murphy knew the first thing he wanted to do was partner with Be The Match.

Not only has the current health crisis been an extremely difficult time for those in need of transplants, as they are immunocompromised, but without community registry events, less have been joining.

This is an action that people can take in 10 minutes for free that can directly save someones life, Mantilla said.

Those interested in being a possible match, can drive up to the event from the safety of their car, where volunteers assist them in registering and administering the 10-second swab test on the inner cheeks while following all health and safety measures.

Were just doing a quick, little swab, and then we send your data out, and we do some research to see if youre possibly even a match, Estarella-Murphy said. Our goal out of this event is to sign up as many individuals as possible, so that through further research, we can then match them to patients awaiting dire transfusions.

Only about 1-in-430 U.S. registry members go on to donate bone marrow or peripheral blood stem cells to a patient.

Thats 0.2% and just emphasizes the need for as many people as possible to be available on the registry because it is so challenging to find that match, Mantilla said, adding that not everyone has an equal chance at finding a match, as ethnic heritage plays a significant role. Right now, the registry is overwhelmingly white. Its a health disparity that is pretty serious as far as equity of access to treatment.

The most common way to harvest stem cells is through a peripheral blood stem cell donation, involving a specialized blood draw, where stem cells are processed from your blood before the blood is returned to the donor.

Your stem cells are a renewable resource, so the donors stem cells actually regenerate in about four to six weeks, Mantilla added.

The event is scheduled 2-6 p.m. Aug. 14, with the location to be determined. For more information, visit biologyclubcoc.org/bethematch. To join the registry, visit join.bethematch.org/COCBio or text COCBio to 61474.

View post:
It's Time to 'Be The Match,' Help Save a Life - SCVNEWS.com

American Academy of Stem Cell Physicians is Hosting an FDA Safety Panel, Session is Now Free to the Public – PRNewswire

MIAMI, July 29, 2020 /PRNewswire/ --An FDA Safety Panel discussion will be held virtually by the American Academy of Stem Cell Physicians (AASCP) Aug.1-3, 2020, with guest speakerFDA Director Dr. Peter Marks. This is a highly anticipated session which will discuss the growing safety concerns of the industry.

The AASCP has recently created guidelines thatare current safety recommendations given to physicians who are using biologics in their medical practice. A highly anticipated and sought-after Safety StandardsPanel session will be hosted VIRTUALLY by AASCP on Aug. 1-3. 2020; guest of honor isDr. Peter Marks, FDA Director of CBER. The sessions normally are closed to the public but this particular SafetyStandard Panel discussion will be open and free to the public, covering the growing safety concerns of the industry.

The Safetypanel discussion will discuss advancements in development, manufacturing and delivery of safe and effective regenerative cell therapies through policy development, consensus and advocacy. The Safety Panel discussion willbringtogether experts and stakeholders to gain consensus on and advocate for policies that will advance the science and the field, including those focused on promoting clinical research, assuring the adoption of consensus standards to promote safety and quality, building capacity and expertise within the workforce, and establishing a national outcomes database to advance the science, promote improvements in quality and safety, and inform regulatory and patient decision-making.

According to AASCP, if physicians are using biologics in their practice, whether they are using SVF, PRP, bone marrow, UCB, amniotic products, exosomes, xenograftsor peptides, there are key considerations to take into account to achieve the best safety for their patients. The AASCP also recommends communication with the Chief Scientific Officer from the laboratory they work with. AASCP advises that just talking to a sales agent is not sufficient enough when determining the quality of products for their patients. Sales agents typically do not have a medical or scientific background.

The President for the AASCP, Dr. Martin Dayton,said earlier: "The American Academy of Stem Cell Physicians is a group of physicians, scientists and researchers who collectively represent the most authoritativenon-federal group advocating for guidelines and education on stem cell therapy and regenerative medicine. AASCP members are experts within all fields of stem cell therapy fromSVF, BM, UCB, Exosomes, Peptides, Xenografts, Allografts and Amniotic Fluids and are considered the most experienced leaders for proper advocacy in the field. The AASCP is involved directly with other authorities within the field and seeks only to bring knowledge and awareness for the ever-growing regenerative medicine industry.My hope is that the SafetyPanel discussion on Aug. 1-3, 2020, is to help get rid of the bad actors that are damaging the field for everyone."

The importance of this virtual conference coincides with the ever-emerging growthof the globalregenerative medicine marketwhich is expected to reachUSD 79.8 billionby 2024, at aCAGR of 20.5%from 2018 to 2024. Factors driving the growth of the market areincreasing prevalence of degenerative and chronic diseases, technological advancements in nanotechnology, bioengineering and stem cell therapy, and increasing geriatric population across the globe.TheAASCP virtual meeting is set for Aug. 1, 2020.List of speakers is available at http://www.aascp.net.

Due to COVID-19, the meeting will take place virtually.Thisis an effective way to ensure that everyone that wishes to participate, but cannot travel, can. Students, educators and physicians will not have to miss out on all the important topics that AASCP has on the pipeline.

Virtual Workshop Lecturers will virtually demonstrate their techniques live via their professional locations. These virtualinteractive workshops will feature small participant-to-instructor ratios with a customized curriculum focusing on developing hands-on skills. Each technique will be taught by experts in the field, using didactic sessions with dynamic multimedia presentations, live demonstrations and scanning on live models, as well as phantoms.

AASCP spokesmanDr. A.J.Farshchianexplains, "We will duplicate everything we did in our past meetings such as offer CME credits, have lectures, workshops, discuss FDA safety standards, have board examinations and a virtual graduation ceremony. AASCP is offering this virtual meeting so that nobody misses out on the education."

To join the free session via Zoom, please click on the link below at 11a.m. this Saturday.

Join Zoom Meeting: https://aascp.zoom.us/j/4150937630

Meeting ID: 415 093 7630

The American Academy of Stem Cell Physicians (AASCP) is a non-profit organization created to advance research and the development of therapeutics in regenerative medicine, including diagnosis, treatment, and prevention of disease related to or occurring within the human body. Secondarily, the AASCPaims to serve as an educational resource for physicians, scientists, and the public in diseases that can be caused by physiological dysfunction that isameliorable to medical treatment.

For further information, please contact MarieBarbaat AASCP at 305-891-4686or visit us at http://www.aascp.net.

Related Images

virtual-conference-aug-1-3-2020.jpeg Virtual Conference Aug. 1-3, 2020

aascp.png AASCP

Related Links

Guest Speaker Dr. Peter Marks, FDA Director

AASCP zoom meeting

SOURCE American Academy of Stem Cell Physicians

More:
American Academy of Stem Cell Physicians is Hosting an FDA Safety Panel, Session is Now Free to the Public - PRNewswire